The British company has announced the results of two studies showcasing the ability of its EpiSwitch platform to diagnose and stage breast cancer and ALS patients.
The multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US, and the firm is also eyeing the Middle East and Africa.
Independent research teams took a look at the mutations, gene fusions, and other alterations that may inform pediatric T-ALL treatment and outcome predictions.
In PLOS this week: gene-environment interactions affecting BMI, transposon mutagenesis study of UTI-linked bacteria, and more.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
In PLOS this week: RNA-directed DNA methylation in Arabidopsis, TLR5 variants linked to melioidosis survival, and more.
The firm's Cxbladder Monitor test was shown to have a high negative predictive value compared to other commercially available urine diagnostic tests for bladder cancer.
Analyses of T cell therapy-responsive metastatic HPV-positive cervical cancers suggest the immune cells largely respond to tumor rather than viral antigens.
Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.
New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.
Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.
La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.
In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.